Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib and TAS-102 in advanced pancreatic cancer
NCT05481463Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2023
- Primary completion
- Mar 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in pancreatic cancer (PC), sponsored by Sun Yat-sen University. Started Jan 2023; status: completed.
02
Drugs
surufatinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05481463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05481463.